Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Our scientists and physicians conduct extensive laboratory and clinical research to identify new treatments and improve therapies for children with hematologic malignancies. Our team's achievements include:
We lead an internationally recognized clinical trials consortium for children and adolescents with newly diagnosed acute lymphoblastic leukemia — the DFCI/ALL Consortium — consisting of 9 institutions in the United States and Canada. We are a founding
member of a small national consortium of leading medical centers that investigate new treatments for children with Hodgkin lymphoma, including innovative drug combinations (and reduced exposure to radiation) that deliver results with fewer long-term complications. In addition, we participate in clinical trials conducted by the Histiocyte Society for patients with
Langerhans cell histiocytosis.
To inquire about clinical trials, email us at firstname.lastname@example.org and read our clinical trial FAQ for answers to general questions.
This research study is a Phase I clinical trial evaluating a drug called ribociclib (LEE011) given in combination with everolimus and other standard of care chemotherapy drugs as a possible treatment for relapsed or refractory acute lymphoblastic leukemia
(ALL). PI: Andrew E. Place, MD, PhD
New Patient Appointments
Find answers to common questions about clinical trials for
childhood cancer, including whether or not a clinical trial may be the right
choice for your child. You can also email your questions to email@example.com